Despite the fact that most ER+ breast cancers initially respond well to ER modulators such as tamoxifen and fulvestrant, one third of the metastatic breast cancers eventually lose ER expression and become resistant to hormone therapy [6, 41, 86]. Here, ESR1 is linked to breast carcinoma.